MONT-SAINT-GUIBERT, Belgium,
October 7, 2013 /PRNewswire/ --
The Belgian biotechnology company Cardio3 BioSciences
(C3BS), a leader in the discovery and development of regenerative,
protective and reconstructive therapies for the treatment of
cardiac diseases, announces the appointment of Dr. Gaëtane Metz as
Chief Operating Officer in view of accelerating the
industrialization process and preparing the commercialization of
its lead product C-Cure®.
Dr. Metz brings to the Company extensive experience in industry,
where she has built experience in Research & Development,
medical affairs and operational excellence including automation to
increase productivity, management of inspection, integration of
production, reorganization and simplification of processes, and
transfer products from R&D to commercial manufacturing.
Prior to joining C3BS, Dr. Metz held the position of Managing
Director of the Life Sciences, Energy and Industry Division at
Altran Europe. Dr. Metz has also held senior and management
positions at CVO CyberConseil, and GlaxoSmithKline Biologicals
(GSK) where she worked for 11 years. Her work included all
aspects and stages of project management, driving the various
departments to collaborate and integrate with one another in order
to speed up processes and increase efficiency.
Dr. Metz holds a PhD in Bioengineering/Biomedical from the Free
University of Brussels (ULB).
Dr. Gaëtane Metz, COO, said: "Cardio3 BioSciences'
pipeline holds great therapeutic potential for significant,
currently unmet medical needs. I am pleased and excited to have the
opportunity to join the Company and lead operations to help the
transition of C-Cure® from late clinical development to a
commercial product."
Dr Christian Homsy, CEO of
Cardio3 BioSciences, commented: "I am delighted to
have Dr Metz join the management team and share her process and
industrialization expertise as we prepare for the commercialization
of our lead product candidate, C-Cure. Dr Metz's expertise in
process development and experience in automation and
industrialization will be instrumental in building the systems that
will provide the foundations for the launch of C-Cure®."
About Cardio3 BioSciences
Cardio3 BioSciences is a Belgian leading biotechnology
company focused on the discovery and development of regenerative
and protective therapies for the treatment of cardiac diseases. The
company was founded in 2007 and is based in the Walloon region of
Belgium. Cardio3 BioSciences
leverages research collaborations in the US and in Europe with Mayo Clinic and the Cardiovascular
Centre Aalst, Belgium.
The Company's lead product candidate C-Cure® is an innovative
pharmaceutical product that is being developed for heart failure
indication. C-Cure® consists of a patient's own cells that
are harvested from the patient's bone marrow and engineered to
become new heart muscle cells that behave identically to those lost
to heart disease. This process is known as Cardiopoiesis.
Cardio3 BioSciences has also developed
C-Cath®ez, the most technologically injection catheter
with superior efficiency of delivery of bio therapeutic agents into
the myocardium.
Cardio3 BioSciences' shares are listed on NYSE Euronext Brussels
and NYSE Euronext Paris under the ticker symbol CARD.
C3BS-CQR-1, C-Cure, C-Cath, Cardio3
BioSciences and the Cardio3 BioSciences and C-Cath logos are
trademarks or registered trademarks of Cardio3 BioSciences SA, in
Belgium, other countries, or both.
Mayo Clinic holds equity in Cardio3 BioSciences as a result of
intellectual property licensed to the company. In addition to
historical facts or statements of current condition, this press
release contains forward-looking statements, which reflect our
current expectations and projections about future events, and
involve certain known and unknown risks, uncertainties and
assumptions that could cause actual results or events to differ
materially from those expressed or implied by the forward-looking
statements. These risks, uncertainties and assumptions could
adversely affect the outcome and financial effects of the plans and
events described herein. These forward-looking statements are
further qualified by important factors, which could cause actual
results to differ materially from those in the forward-looking
statements, including timely submission and approval of anticipated
regulatory filings; the successful initiation and completion of
required Phase III studies; additional clinical results validating
the use of adult autologous stem cells to treat heart failure;
satisfaction of regulatory and other requirements; and actions of
regulatory bodies and other governmental authorities. As a result,
of these factors investors and prospective investors are cautioned
not to rely on any forward-looking statements. We disclaim
any intention or obligation to update or review any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information contact:
Cardio3 BioSciences
Dr Christian Homsy, CEO
Anne Portzenheim, Communication Manager
http://www.c3bs.com
Tel : +32-10-39-41-00
aportzenheim@c3bs.com
Citigate Dewe Rogerson
Chris Gardner
Tel : +44(0)207-638-9571